A 6-week Phase 2a Randomized, Double-blind, Placebo-controlled, Parallel Group Study To Assess Safety, Tolerability And Pharmacodynamics Of Oral Pf-05175157 As Monotherapy In Subjects With Type 2 Diabetes Mellitus
Phase of Trial: Phase II
Latest Information Update: 20 Feb 2017
At a glance
- Drugs PF 5175157 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 31 Aug 2018 Biomarkers information updated
- 01 Jul 2014 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
- 05 May 2014 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.